Reuters -- GlaxoSmithKline Plc, the world's second-largest drugmaker, has signed a deal potentially worth $200 million with British biotech company Vernalis Plc (VER.L) to boost its early-stage research in cancer.
Reuters -- GlaxoSmithKline Plc, the world's second-largest drugmaker, has signed a deal potentially worth $200 million with British biotech company Vernalis Plc (VER.L) to boost its early-stage research in cancer.
